This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-PS IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the PS as well as the biological activity of IL2. 2aG4-IL2 has great improvement than 2aG4 and IL2 alone. First, the improvement is antigen-specific indicating that 2aG4-IL2 blocks PS-dependent immunosuppressive signals. Second, the improvement is greater with 2aG4-IL2 than with 2aG4 alone, indicating that immunostimulatory cytokine-IL2 contributes to the vaccination. This immunocytokine was designed for treating PS-expressing tumor.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-819 | Recombinant Anti-PS Antibody | ELISA, WB, Dot, FuncS | IgG |
MHH-819 | Recombinant Human Anti-PS Antibody | WB, IP, FuncS | IgG |
PABZ-170 | Human Anti-PS Recombinant Antibody (clone pSTAb) | ELISA, WB | Humanized IgG |
PABZ-172 | Human Anti-PS Recombinant Antibody (clone pSAb) | ELISA, WB | Humanized IgG |
PABZ-173 | Human Anti-PS Recombinant Antibody (clone pYAb) | ELISA, WB | Humanized IgG |
There are currently no Customer reviews or questions for ACFP-SH006. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.